{'52WeekChange': -0.4445964,
 'SandP52WeekChange': 0.0644362,
 'address1': '4301 Emperor Boulevard',
 'address2': 'Suite 400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.29,
 'askSize': 1200,
 'averageDailyVolume10Day': 503225,
 'averageVolume': 886017,
 'averageVolume10days': 503225,
 'beta': 1.055462,
 'beta3Year': None,
 'bid': 12,
 'bidSize': 3100,
 'bookValue': 2.737,
 'category': None,
 'circulatingSupply': None,
 'city': 'Durham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.52,
 'dayLow': 12.02,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.204,
 'enterpriseToRevenue': 6.444,
 'enterpriseValue': 511528352,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 14.247143,
 'fiftyTwoWeekHigh': 26.26,
 'fiftyTwoWeekLow': 10.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42921333,
 'forwardEps': -2.11,
 'forwardPE': -5.7725124,
 'fromCurrency': None,
 'fullTimeEmployees': 380,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0208,
 'heldPercentInstitutions': 1.3145399,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aeriepharma.com',
 'longBusinessSummary': 'Aerie Pharmaceuticals, Inc., an ophthalmic '
                        'pharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of first-in-class '
                        'therapies for the treatment of glaucoma, dry eye, '
                        'retinal diseases, and other eye diseases. Its '
                        'products include Rhopressa, a once-daily eye drop to '
                        'reduce elevated intraocular pressure (IOP) in '
                        'patients with glaucoma or ocular hypertension; and '
                        'Rocklatan, a once-daily fixed-dose combination of '
                        'Rhopressa and latanopros to reduce IOP to treat '
                        'patients with open-angle glaucoma and ocular '
                        'hypertension. The company is also developing AVX-012, '
                        'a clinical-stage dry eye product candidate; and '
                        'AR-1105 and AR-13503 sustained-release implants for '
                        'treating retinal diseases. Aerie Pharmaceuticals, '
                        'Inc. has a collaborative research, development, and '
                        'licensing agreement with DSM. Aerie Pharmaceuticals, '
                        'Inc. was founded in 2005 and is headquartered in '
                        'Durham, North Carolina.',
 'longName': 'Aerie Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 565983936,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24309870',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -200759008,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.52,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.06,
 'phone': '919 237 5300',
 'previousClose': 12.61,
 'priceHint': 2,
 'priceToBook': 4.450128,
 'priceToSalesTrailing12Months': 7.1303267,
 'profitMargins': -2.52918,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.52,
 'regularMarketDayLow': 12.02,
 'regularMarketOpen': 12.52,
 'regularMarketPreviousClose': 12.61,
 'regularMarketPrice': 12.52,
 'regularMarketVolume': 485372,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46468300,
 'sharesPercentSharesOut': 0.1936,
 'sharesShort': 8998241,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9864876,
 'shortName': 'Aerie Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.2672,
 'shortRatio': 10.12,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'AERI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.407,
 'twoHundredDayAverage': 16.296223,
 'volume': 485372,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aeriepharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27703'}